Invivyd (NASDAQ:IVVD) shares gained 2.2% after the company revealed a new partnership with Olympic gold medalist Lindsey Vonn to support a nationwide educational initiative focused on antibodies.
The campaign, scheduled to roll out in spring 2026, will see Vonn act as the public face of the programme, coinciding with her expected return to competitive skiing and bid to qualify for the 2026 Winter Games. The effort is designed to raise awareness among U.S. audiences about antibodies and their role as proteins that help the body defend itself against infections.
Invivyd, which specialises in antibody-based therapeutics, said the collaboration is intended to broaden public understanding of immune science while boosting the company’s profile in health education. By aligning with a high-profile athlete, the group aims to communicate complex scientific concepts in a more accessible way.
The timing of the initiative is seen as strategic, aligning with heightened media attention around Vonn’s comeback and the build-up to the 2026 Winter Olympics, which could significantly amplify the campaign’s reach.
Market reaction suggested investors welcomed the announcement, viewing the partnership as a positive branding and awareness move that could support Invivyd’s longer-term positioning as it advances its antibody-focused pipeline.